Becton Dickinson and : BD Collaborates with GOCC to Combat Sepsis in Poland

Program Expands Access to Advanced Testing for Bloodstream Infections and Sepsis Management at More Than 150 Hospitals and Clinics

WARSAW (March 14, 2024) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with GOCC (The Great Orchestra of Christmas Charity), the largest non-governmental non-profit organization in Poland, to expand access to advanced testing for bloodstream infections (BSIs) and sepsis management at more than 150 Polish hospitals and clinics.

The GOCC program includes the installation of state-of-the-art BD microbiology equipment across the country, including the BD™ Bruker MALDI Biotyper® sirius IVD System for the identification of microorganisms and BD Phoenix™ M50 Systems for automatic bacterial identification and drug-susceptibility testing of microorganisms. These instruments can help enable clinicians to make critical patient management decisions with speed and accuracy.

Sepsis is a serious medical condition that results from the body's overwhelming and life-threatening response to a bloodstream infection¹. Patients may experience multiple organ system failures, shock and even death within just a few hours, so rapid diagnosis is crucial for implementing effective, targeted treatment as soon as possible. It is a leading cause of hospital readmissions with an estimated 47 million to 50 million cases occurring worldwide each year with 11 million deaths^2,3. Faster time to detection and determination of appropriate antimicrobial therapy aided by the guidance of robust identification and susceptibility technology facilitate the critical steps towards targeted treatment⁴.

"This broad deployment aligns with BD's commitment to help advance access and health equity and it also supports the mission of GOCC to improve health care in Poland by making medical services more modern and accessible," said Davide Visentin, vice president and general manager, BD Integrated Diagnostic Solutions, Europe/Middle East/Africa. "Advanced microbial detection in more locations enables quicker diagnosis of bloodstream infections. We can identify the bug and the drug to help inform appropriate antimicrobial treatment. For patients with sepsis, every hour is critical."

The BD™ Bruker MALDI Biotyper® and the BD Phoenix™ M50 systems are essential parts of the integrated BD BSI Solution, which offers a sample collection to results reporting workflow to aid in the detection and management of BSIs and sepsis. The BD™ Bruker MALDI Biotyper® sirius IVD System identifies microorganisms using MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) mass spectrometry. The BD Phoenix™ M50 System provides clinicians accurate and timely identification and susceptibility results of clinically significant organisms to help guide therapy and patient management decisions. More information on the integrated BD BSI Solution to address the growing management needs around sepsis and BSIs is available at https://www.bd.com/en-us/products-and-solutions/solutions/bloodstream-infection.

1. https://www.sepsis.org/sepsis-basics/what-is-sepsis/
2. Mayr FB et al. Proportion and Cost of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical Conditions. JAMA. 2017
3. Rudd K et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. 2020
4. Adrie et al. (2017). Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy. Journal of Infection. 74: 131-141

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.

Contacts:

Attachments

• Original Link
• Permalink

Disclaimer

BD - Becton, Dickinson and Company published this content on 14 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 March 2024 12:57:18 UTC.